Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

Completed · Phase 4

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

This trial is conducted in the United States of America (USA). The aim of this trial is to compare the effect of repaglinide on postprandial lipemia in subjects with type 2 diabetes.

Key facts

Study ID

NCT01605773

Run by

Novo Nordisk A/S

People needed

51

Starts

2001-11-08

Expected to finish

2003-03-13

Last updated by the study team

2017-02-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Newly diagnosed patients with type 2 diabetes currently treated with diet and exercise alone (HbA1c below 10%)
• Subjects with type 2 diabetes treated with sulphonylurea (HbA1c below 8.5%)
• Males or non-pregnant, non-lactating females
• Subjects should have normal renal function

You may not qualify if…

• Type 1 or other specific causes of diabetes
• Marked symptomatic diabetes
• Uncontrolled treated/untreated hypertension
• Known or suspected allergy to the trial products or related products

Where it is running

• Novo Nordisk Investigational Site — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.